-
Indaptus Therapeutics (INDP) Files $100M Mixed Shelf
-
Indaptus Therapeutics (INDP) Announces Additional Sale of $3.4M in Private Placement of Convertible Notes and Warrants
-
Indaptus Therapeutics (INDP) Announces Reverse Share Split
-
Indaptus Therapeutics (INDP) Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
-
Indaptus Therapeutics, Inc. (INDP) Misses Q1 EPS by 14c
-
Indaptus Therapeutics (INDP) Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
-
Indaptus Therapeutics (INDP) Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
-
Indaptus Therapeutics (INDP) expands Patent Portfolio in China, Japan, and Israel
-
Indaptus Therapeutics (INDP) Files for 4.37M Share Offering by Selling Stockholders
-
Indaptus Therapeutics (INDP) Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
-
Indaptus Therapeutics (INDP) Provides Year-End Review and Outlook for 2025
-
Indaptus Therapeutics (INDP) Files for 1.94M Share Offering by Selling Stockholders
-
Indaptus Therapeutics (INDP) Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement
-
Indaptus Therapeutics, Inc. (INDP) Tops Q3 EPS by 16c
-
Indaptus Therapeutics (INDP) Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20
-
Indaptus Therapeutics (INDP) Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations
-
H.C. Wainwright Reiterates Buy Rating on Indaptus Therapeutics (INDP)
-
Indaptus Therapeutics, Inc. (INDP) Tops Q2 EPS by 11c
-
Indaptus Therapeutics (INDP) Announces 1.64M Share Offering at $1.825/sh

